278 related articles for article (PubMed ID: 34889401)
1. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
Epperla N; Hamadani M
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
3. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma.
Fernández KS; Mavers M; Marks LJ; Agarwal R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e191-e194. PubMed ID: 31876780
[TBL] [Abstract][Full Text] [Related]
5. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
Grover NS; Dittus C; Thakkar A; Beaven AW
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
[TBL] [Abstract][Full Text] [Related]
6. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
10. Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective.
Iqbal M; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):95-103. PubMed ID: 32603659
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
12. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.
Kanate AS; Kumar A; Dreger P; Dreyling M; Le Gouill S; Corradini P; Bredeson C; Fenske TS; Smith SM; Sureda A; Moskowitz A; Friedberg JW; Inwards DJ; Herrera AF; Kharfan-Dabaja MA; Reddy N; Montoto S; Robinson SP; Abutalib SA; Gisselbrecht C; Vose J; Gopal A; Shadman M; Perales MA; Carpenter P; Savani BN; Hamadani M
JAMA Oncol; 2019 May; 5(5):715-722. PubMed ID: 30816957
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner MA; Sica RA; Tamaresis JS; Lu Y; Chang C; Lowsky R; Frank MJ; Johnston LJ; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shiraz P; Shizuru JA; Weng WK; Binkley MS; Hoppe RT; Advani RH; Arai S
Blood; 2023 Jun; 141(22):2727-2737. PubMed ID: 36857637
[TBL] [Abstract][Full Text] [Related]
15. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
16. Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.
Dahi PB; Moskowitz CH; Giralt SA; Lazarus HM
Expert Rev Hematol; 2019 Apr; 12(4):255-264. PubMed ID: 30874456
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
[TBL] [Abstract][Full Text] [Related]
20. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition.
Belia M; Chatzidimitriou C; Rondogianni P; Petsa P; Efstathopoulou M; Konstantinou E; Arapaki M; Asimakopoulos J; Plata E; Konstantopoulos K; Angelopoulou MK; Vassilakopoulos TP
Hematol Oncol; 2021 Apr; 39(2):258-262. PubMed ID: 32905619
[No Abstract] [Full Text] [Related]
[Next] [New Search]
